60 Degrees Pharmaceuticals, Inc. ( (SXTP) ) has released its Q2 earnings. Here is a breakdown of the information 60 Degrees Pharmaceuticals, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and marketing new medicines for infectious diseases, with its headquarters in Washington, D.C. The company recently released its earnings report for the second quarter of 2025, highlighting a continued focus on its lead product, ARAKODA®, for malaria prevention, and ongoing development programs for other diseases. Despite a net loss of $1.73 million for the quarter, the company reported a gross profit increase to $50,881, driven by a rise in research revenues. Operating expenses remained high at $1.86 million, primarily due to research and development and general administrative costs. Looking ahead, 60 Degrees Pharmaceuticals plans to continue its efforts to achieve profitability through additional capital raising and strategic initiatives, while addressing the challenges of the competitive biopharmaceutical industry.